| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A carbonic anhydrase inhibitor used as diuretic and in glaucoma. It may cause hypokalemia. [PubChem] |
| Indication |
For use in the treatment of duodenal ulcers, as a diuretic, and in the treatment of glaucoma, and may also be useful in the treatment of seizures associated with epilepsy. |
| Pharmacology |
Ethoxzolamide, a sulfonamide, inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate. It also decreases carbonic anhydrase in the CNS, increasing the seizure threshold. This reduction in carbonic anhydrase also reduces the intraocular pressure in the eye by decreasing aqueous humor. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Absorption |
Rapidly absorbed with 65% bioavailability |
| Half Life |
2.5-5.5 hours |
| Protein Binding |
~89% |
| External Links |
|
|